new york  reuters    a u s  house of representatives committee launched a probe into drugmaker allergan plc s  agn n  deal to transfer some of its patents to a native american tribe to shield them from review  a bipartisan group of four representatives from the house oversight and government committee  including republican chairman trey gowdy and top democrat elijah cummings  sent a letter to the company on tuesday saying the arrangement could  impair competition across the pharmaceutical industry   allergan said last month that it was transferring patents on its dry eye medication restasis to new york s saint regis mohawk tribe  which agreed to exclusively license them back to the company in exchange for ongoing payments   the representatives asked allergan to provide documents about its agreements with the tribe  financial details about the drug covered by the patents and documents on whether the drugmaker is considering similar arrangements for its other drugs  allergan said it plans to cooperate with the committee s requests  the company s shares closed down     or   percent  at    on tuesday  allergan has argued that the legal maneuver is aimed at removing administrative patent challenges through inter partes review  ipr  by the u s  patent trial and appeal board  and not challenges in federal court  the drugmaker said it believes that the patents should not be subject to the ipr process because of the tribe s sovereign immunity   the company still faces a challenge to the patents in federal court and has said that it does not plan to invoke the tribe s immunity in federal court  still  some legal experts say the maneuver could also be used to protect patents from challenges in federal court as well  earlier on tuesday  allergan chief executive brent saunders defended the transactions as a proper way to shield the patents from the  flawed and broken  ipr process  saunders sent a letter to republican senator charles grassley and democratic senator dianne feinstein  the chairman and ranking member of the senate judiciary committee   after four democratic u s  senators asked them to launch a committee investigation into the deal last week  allergan competitor mylan nv myl n  which is challenging the patents through the ipr process  has called allergan s deal with the tribe a  sham transaction  and said the tribe should not be allowed to invoke immunity     the patent board has previously recognized the immunity of state entities such as public universities  and tribal immunity is considered by some to be an even stronger shield  